Penn Researcher and CVS Health Physician Urge New Payment Model for Costly Gene Therapy Treatments

Hoping to encourage sufficient investments by pharmaceutical companies in expensive gene therapies, which often consist of a single treatment, a Penn researcher and the chief medical officer of CVS Health outline an alternative payment model in this month’s issue of Nature Biotechnology.